German medical company Beiersdorf has acquired from Kendall of the USA a plant in Ohio and two medical product (plasters and bandages) brands. The deal is valued at around $150 million.
Beiersdorf says that it expects its medical division sales to expand to around 2 billion Deutschemarks ($1.4 billion) by the year 2000, mainly through the development of new products at an accelerated pace. There are also growth prospects in the dermatology sector, according to the company, and for products to treat problems in blood vessels and in wound care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze